4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl)phenyl)benzamide
4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl)phenyl)benzamide Basic information
- Product Name:
- 4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl)phenyl)benzamide
- Synonyms:
-
- 4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl)phenyl)benzamide
- Benzamide, 4-(2H-tetrazol-5-yl)-N-[4-(2H-tetrazol-5-yl)phenyl]-
- Andolast (Synonyms: CR 2039
- Dizolast)
- CR 2039
- CR2039
- CR-2039
- Andolast free base
- CAS:
- 132640-22-3
- MF:
- C15H11N9O
- MW:
- 333.31
- Mol File:
- 132640-22-3.mol
4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl)phenyl)benzamide Chemical Properties
- Density
- 1.551±0.06 g/cm3(Predicted)
- pka
- 3.78±0.10(Predicted)
- form
- Solid
- color
- White to off-white
4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl)phenyl)benzamide Usage And Synthesis
Uses
Andolast (CR 2039) (free base) is an anti-allergic agent. Andolast can inhibit cAMP-phosphodiesterase with an IC50 value of 50 μM. Andolast can be used for the research of asthma[1].
in vivo
Andolast (CR 2039) (i.v. or i.m.) inhibits rat passive cutaneous anaphylaxis (PCA) with an ED50 of 0.1 mg/kg[1].
CR 2039 (10-100 mg/kg; i.v. or i.m.) inhibits the microvascular permeability changes in a model of allergic conjunctivitis in sensitized guinea-pigs[1].
CR 2039 (0-1000 μM; i.v.) inhibits dose dependently guinea-pig lung cAMP-phosphodiesterase with an IC50 value of 50 μM[1].
| Animal Model: | Male Hartley guinea-pigs (300-500 g) [1] |
| Dosage: | 10-100 mg/kg |
| Administration: | I.M; I.V. |
| Result: | Showed dose-related significant protection against lgE-dependent bronchial anaphylaxis induced by aerosolized antigen in anesthetized guinea-pigs. Delayed dose dependently the onset of bronchoconstriction induced by aerosolized antigen. |
References
[1] Revel L, Colombo S, Ferrari F, Folco G, Rovati LC, Makovec F. CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma. Eur J Pharmacol. 1992;229(1):45-53. DOI:10.1016/0014-2999(92)90284-b
[2] Czuczwar SJ, Gasior M, Kozicka M, Pietrasiewicz T, Turski WA, Kleinrok Z. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. Eur Neuropsychopharmacol. 1998;8(3):233-238. DOI:10.1016/s0924-977x(97)00077-1
4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl)phenyl)benzamideSupplier
- Tel
- sales@boylechem.com
- Tel
- 86(21)68097365
- sales@anpharma.net
- Tel
- 21-619849051-1 18521059765
- synchempharma@aliyun.com
- Tel
- +86 18721201413
- sales@biopharmaleader.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com